fbpx Skip to main content
Janssen is now J&J Innovative Medicine.    |  
 
 
 
 
MENU CLOSE
 

JANSSEN GLOBAL
CHANGE LOCATION >

Search
Search
Home › ASH 2020 Newsroom

ASH 2020 Newsroom

ASH 2020 Newsroom
Janssen Oncology
ASH 2020 Newsroom
Janssen Oncology
You are entering Janssen’s ASH Virtual Newsroom, which features the latest news and data from the conference. Press releases and other materials may contain information for unapproved treatments or indications.
Yes
Cancel

The American Society of Hematology (ASH) has moved to a virtual platform for the 2020 Annual Meeting, and Janssen Oncology will have a strong showing at ASH with more than 35 company-sponsored presentations highlighting our deep, diverse oncology pipeline and portfolio.

Thank you for visiting the Janssen Oncology newsroom to learn more about our innovative approaches to advance science and deliver transformational medicines for patients
diagnosed with cancer.

You can learn more about what Janssen is doing to address the COVID-19 pandemic here.

 

Leadership Perspectives

 

Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
Janssen Research & Development, LLC.

Serge Messerlian
President, Janssen Oncology
Janssen Pharmaceuticals, Inc.

Latest News

 
 
Janssen Headlines American Society of Hematology Annual Meeting with More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
 
 
STAT News: Advances in understanding and treating multiple myeloma
 
New APOLLO Study Data in Relapsed/Refractory Multiple Myeloma
 
IMBRUVICA® Combo Offers Disease-Free Survival with Fixed Treatment Duration for First-Line CLL
 
CAR-T Therapy Cilta-cel Shows Early, Deep and Durable Responses in Heavily Pretreated Multiple Myeloma
 
Updated Efficacy for BCMAxCD3 Bispecific Antibody in Heavily Pretreated Multiple Myeloma
 
First Data for GPRC5DxCD3 Bispecific Talquetamab in Relapsed/Refractory Multiple Myeloma
 
IMBRUVICA® Offers Long-Term Benefit in High-Risk CLL
 
DARZALEX® Data Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma
 
Data Show Hematologic Response for DARZALEX FASPRO® in Newly Diagnosed Light Chain (AL) Amyloidosis

Patient Advocate Perspectives

 

Myeloma Teacher Shares Hope for Multiple Myeloma Patients

CLL Patient Advocate Insight on Educating Yourself After Diagnosis

 

Follow @JanssenGlobal for more news and information during ASH 2020!